Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The refugee influx started the day after Sunday’s vote and since then dozens of people have been arriving at a time, said Irene Nakasiita, a spokeswoman for the Red Cross in Uganda. Some Congolese trying to cross the border were forced back after resisting the efforts of Ugandan health officials screening people for Ebola, she said. Congo’s government cited the Ebola outbreak in the country’s northeast for a contentious decision to bar an estimated 1 million voters from the election. Protests followed, with some people vandalizing Ebola response facilities and some aid groups forced to suspend work for days. The internet has been cut off in Congo this week in an apparent effort by the government to prevent social media speculation about the results, while the opposition and observers have reported multiple problems with the election. The internet outage also has affected Ebola response efforts, with Congo’s health ministry on Wednesday citing “technical problems” for the delay in sending its daily update on the outbreak. More than 600 Ebola cases have been reported, with more than 360 confirmed deaths since August. The outbreak is the second-deadliest in history. The outbreak has been difficult to control amid armed violence and community protests, and the violence has increased “in intensity and frequency,” the head of the World Health Organization said Wednesday. And yet “there is reason to be hopeful” the outbreak will be brought under control as soon as possible, Tedros Adhanom Ghebreyesus said in the Ugandan capital, Kampala. He spent New Year’s Day in Congo. Amid the election-related protests last week, Tedros warned that “prolonged insecurity” in Congo could lead to a rise in new Ebola cases. Some of the Ebola cases in this outbreak have been reported close to the heavily traveled border with Uganda. For months, Ugandan officials have been subjecting all passing through official border posts to mandatory Ebola screening. The Ebola virus is spread through direct contact with the fluids of an infected person. More than 50,000 people have received an experimental vaccine. Tedros said there were enough doses of the vaccine available “but at the same time we have already requested the supplier to produce more.” ___ Follow Africa news at https://twitter.com/AP_Africa Claim: Congolese flee to Uganda after vote, raising Ebola fears.

A: Hundreds of refugees have crossed into Uganda from Congo in the days since that country’s troubled presidential election, a Red Cross official said Wednesday, heightening concerns about the possible cross-border spread of Ebola. Separately, the head of the World Health Organization said he has asked the supplier of an experimental vaccine to produce more of it.
****
Q: Paragraph: The Medicines and Healthcare products Regulatory Agency (MHRA) said it was investigating 14 fake or unlicensed products to treat COVID-19, the respiratory disease caused by the coronavirus. So far 3,605 Britons have died from the coronavirus, the latest data show, and experts have said deaths will continue to rise until the effect of recent lockdown measures filter through and slow the spread of the disease in the coming weeks. MHRA said it was investigating fake self-testing kits, miracle cures and so-called “antiviral misting sprays”. “Don’t be fooled by online offers for medical products to help prevent or treat COVID-19,” Lynda Scammell, MHRA enforcement official said. “There is no medicine licensed specifically to treat or prevent COVID-19, therefore any claiming to do so are not authorised and have not undergone regulatory approvals required for sale on the UK market.”  Scammell added that MHRA was working alongside law enforcement agencies to combat the spread of fake and unlicensed medical products. Claim: Miracle cures? UK investigators go after fake coronavirus medicines.

A: British authorities said on Saturday they were clamping down on bogus cures for the coronavirus, which currently has no specific licensed treatment.
****
Q: Paragraph: Calquence (acalabrutinib) belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors which can suppress autoimmune diseases. The drug, which is currently used to treat certain types of blood cancers, has already been approved for the treatment of adult patients with chronic lymphocytic leukaemia in the U.S. and several other countries. Calquence competes with AbbVie Inc (ABBV.N) and Johnson & Johnson’s (JNJ.N) established treatment Imbruvica as a treatment for chronic lymphocytic leukemia, one of the most common types of leukemia in adults. The British drugmaker’s shares rose as much as 7.3% to 7642 pence by 0855 BST. AstraZeneca’s announcement comes as drugmakers are having to pause clinical trials for other disease areas as they focus on testing potential treatments for the fast-spreading coronavirus. Patients with severe symptoms including pneumonia are believed to suffer from an over reaction of the immune system known as cytokine storm and AstraZeneca aims to test whether Calquence, which suppresses certain elements of the immune system, can help control this immune response. “Given the well documented role of the protein BTK in regulating inflammation, it is possible that inhibiting BTK with acalabrutinib could provide clinical benefit in patients with advanced COVID-19 lung disease,” said Louis Staudt, chief of the lymphoid malignancies branch at the National Cancer Institute. The trial will evaluate the effectiveness and safety of adding the drug to best supportive care to reduce mortality and the need for assisted ventilation in patients with life-threatening COVID-19 symptoms, the drugmaker said. It is expected to open for enrolment in the coming days in the U.S. and several countries in Europe, AstraZeneca said. Earlier this month, AstraZeneca and its domestic rival GlaxoSmithKline PLC (GSK.L) agreed to set up a testing laboratory to aid in COVID-19 testing with Cambridge University. Claim: AstraZeneca to test impact of cancer drug Calquence on coronavirus patients.

A:
AstraZeneca Plc (AZN.L) said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with COVID-19 infection in severely ill patients.
****